Liu B, Cao PK, Wang YZ, Wang WJ, Tian SL, Hertzanu Y, Li YL. Modified percutaneous transhepatic papillary balloon dilation for patients with refractory hepatolithiasis. World J Gastroenterol 2020; 26(27): 3929-3937 [PMID: 32774067 DOI: 10.3748/wjg.v26.i27.3929]
Corresponding Author of This Article
Yu-Liang Li, MD, Chief Doctor, Professor, Department of Interventional Medicine, The Second Hospital of Shandong University; Interventional Oncology Institute of Shandong University, No. 247, Beiyuan Road, Jinan 250033, Shandong Province, China. lyl.pro@sdu.edu.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Liu B, Cao PK, Wang YZ, Wang WJ, Tian SL, Hertzanu Y, Li YL. Modified percutaneous transhepatic papillary balloon dilation for patients with refractory hepatolithiasis. World J Gastroenterol 2020; 26(27): 3929-3937 [PMID: 32774067 DOI: 10.3748/wjg.v26.i27.3929]
World J Gastroenterol. Jul 21, 2020; 26(27): 3929-3937 Published online Jul 21, 2020. doi: 10.3748/wjg.v26.i27.3929
Modified percutaneous transhepatic papillary balloon dilation for patients with refractory hepatolithiasis
Bin Liu, Pi-Kun Cao, Yong-Zheng Wang, Wu-Jie Wang, Shi-Lin Tian, Yancu Hertzanu, Yu-Liang Li
Bin Liu, Yong-Zheng Wang, Wu-Jie Wang, Yancu Hertzanu, Yu-Liang Li, Department of Interventional Medicine, The Second Hospital of Shandong University, Jinan 250033, Shandong Province, China
Bin Liu, Yong-Zheng Wang, Wu-Jie Wang, Yancu Hertzanu, Yu-Liang Li, Interventional Oncology Institute of Shandong University, Jinan 250033, Shandong Province, China
Pi-Kun Cao, Department of Cancer Center, The First Affiliated Hospital of Shandong First Medical University, Jinan 250014, Shandong Province, China
Shi-Lin Tian, School of Medicine, Shandong University, Jinan 250014, Shandong Province, China
Author contributions: Liu B contributed to the study concept and design, analysis and interpretation of the data, drafting of the manuscript, and statistical analysis, and obtained funding; Cao PK contributed to the acquisition of data, analysis and interpretation of data, and statistical analysis; Wang YZ contributed to the technical support and critical revision of the manuscript for important intellectual content; Wang WJ contributed to the technical support and statistical analysis; Tian SL contributed to the acquisition of data and material support; Hertzanu Y contributed to the critical revision of the manuscript for important intellectual content; Li YL contributed to the study concept and design, study supervision, critical revision of the manuscript for important intellectual content, and obtained funding.
Supported byNatural Science Foundation of Shandong Province, No. ZR2018PH032 and No. ZR2018PH033; and National Natural Science Foundation of China, No. 61671276 and No. 11971269.
Institutional review board statement: This study was approved by the ethics committee of the Second Hospital of Shandong University, No. KYLL-2014(LW)02.
Informed consent statement: All participants provided written informed consent.
Conflict-of-interest statement: All authors declare no conflicts-of-interest related to this article.
Data sharing statement: No additional data are available.
Corresponding author: Yu-Liang Li, MD, Chief Doctor, Professor, Department of Interventional Medicine, The Second Hospital of Shandong University; Interventional Oncology Institute of Shandong University, No. 247, Beiyuan Road, Jinan 250033, Shandong Province, China. lyl.pro@sdu.edu.cn
Received: May 6, 2020 Peer-review started: May 6, 2020 First decision: May 21, 2020 Revised: May 24, 2020 Accepted: July 4, 2020 Article in press: July 4, 2020 Published online: July 21, 2020 Processing time: 76 Days and 0.5 Hours
ARTICLE HIGHLIGHTS
Research background
The treatment of hepatolithiasis is complicated and difficult. Some patients cannot tolerate surgery due to severe cardiac or pulmonary comorbidities, or cannot be treated with endoscopy because of altered gastrointestinal anatomies.
Research motivation
Our previous experience indicated percutaneous transhepatic papillary balloon dilation (PTPBD) could be an alternative for common bile duct stones.
Research objectives
In this retrospective study, the clinical efficacy and safety of modified PTPBD were assessed for the removal of intrahepatic bile duct stones in patients with cardiopulmonary comorbidities or altered gastrointestinal anatomies.
Research methods
Twenty-one patients with intrahepatic bile duct stones who underwent modified PTPBD were enrolled in this study. Outcomes, including success rate, cause of failure, complications, procedure time and hospital stay, were analyzed. Reflux cholangitis and calculi recurrence were recorded for 2 years.
Research results
The success rate was 95.23%. No pancreatitis or perforation occurred. No evidence of reflux cholangitis and calculi recurrence were observed for 2 years.
Research conclusions
Modified PTPBD could be considered as a safe, feasible, and effective treatment option for intrahepatic bile duct stones in patients with cardiopulmonary comorbidities or altered gastrointestinal anatomies.
Research perspectives
Multi-center prospective study should be conducted to compare modified PTPBD to surgery or endoscopic procedures to gain more evidence.
